Month: August 2020

 Geneva, Switzerland and Boston, MA –  August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Wedbush PacGrow Virtual Healthcare Conference taking place August 11 – 12, 2020.Mr. Loumaye’s presentation will take place on Wednesday August 12, 2020 at 9:45 a.m. Eastern Time (ET).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development,...

Press Release  Regulated Information Inside Information August 7, 2020, 7:00 CETIRVINE, CA and HERSTAL, BELGIUM – August 7, 2020 – MDxHealth SA (Euronext Brussels: MDXH), a commercial-stage innovative molecular diagnostics company, today reports an update and associated delay in obtaining Medicare coverage for its SelectMDx for Prostate Cancer test. In August 2019, Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its Molecular Diagnostic Services (MolDx) program, issued a positive draft local coverage determination (LCD) recommending coverage for the SelectMDx test.  Following recent communications with Palmetto GBA related to the retirement of the previously issued draft LCD, the Company has been requested to submit an update to our technical assessment under the MolDx program...

Communiqué de Presse  Information Réglementée. Information Privilégiée. 7 août 2020, 7H00 HECIRVINE, CA et HERSTAL, BELGIQUE – le 7 août 2020 – MDxHealth SA (Euronext Brussels: MDXH), une société de diagnostic moléculaire innovante en phase de commercialisation, annonce aujourd’hui une mise à jour et un retard associé dans l’obtention de la couverture Medicare pour son test SelectMDx for Prostate Cancer.En août 2019, Palmetto GBA, un Entrepreneur Administratif de Medicare (Medicare Administrative Contractor – MAC) qui évalue les technologies de diagnostic moléculaire dans le cadre de son programme de Services de Diagnostic Moléculaire (Molecular Diagnostic Services – MolDx), a publié un projet de détermination de couverture locale (Local Coverage Determination – LCD) positif, recommandant la couverture pour...

In Q2 2020 Inbank earned a net profit of 556 thousand euros. The 2020 half-year net profit was 2.7 million euros. The return on equity in Q2 was 4,5%.Q2 net profit decreased by 76% compared to Q2 2019, from 2.3 million euros to 556 thousand.Profit before loan losses for the quarter increased by 10% and amounted to 4.3 million euros. Provisions for loan losses increased by 113% to 3.7 million euros.Inbank loan portfolio increased 27% compared to Q2 2019 reaching 349 million euros while the deposit portfolio grew 47%, reaching 402 million euros at the end of Q2.Total sales for Q2 was 60 million euros, showing a decrease of 19% compared to Q2 of the previous year. In terms of products, personal loan sales decreased by 72% and car financing products by 28% while the sales finance volumes increased by 12% compared to the previous year.By the...

Inbanki 2020. aasta teise kvartali puhaskasum oli 556 tuhat eurot ja esimese poolaasta puhaskasum oli 2,7 miljonit eurot. Omakapitali tootlus oli teises kvartalis 4,5%.2020. aasta teise kvartali puhaskasum langes eelmise aasta sama perioodiga võrreldes 76% ehk 2,3 miljonilt eurolt 556 tuhandele eurole.Kvartali kasum enne laenukahjumeid kasvas 10% ja ulatus 4,3 miljoni euroni. Eraldised laenukahjumite katteks kasvasid 113% ja olid 3,7 miljonit eurot.Inbanki laenuportfell kasvas 2019. aasta teise kvartaliga võrreldes 27% ja ulatus kvartali lõpuks 349 miljoni euroni. Hoiuseportfell kasvas aastaga 47% ja oli 2020. aasta teise kvartali lõpuks 402 miljonit eurot.Teise kvartali müügimaht oli kokku 60 miljonit eurot. Eelmise aasta teise kvartaliga võrreldes langes see 19%. Toodete lõikes vähenes väikelaenu müük 72% ja autofinantseerimistooted...

Corbion reported sales of € 492.2 million in the first half of 2020, an increase of 4.3% due to organic net sales growth of 4.0% and positive currency effects. Organic net sales growth in Core activities was 5.3%. Adjusted EBITDA increased organically by 16.9% to € 83.8 million due to improvements in all business segments.“The Covid-19 pandemic has had a profound impact throughout the first half of 2020. I am therefore particularly proud of the Corbion teams’ dedication and execution excellence to drive sales and profit growth in the first half while all our plants continued to operate in uncertain and challenging times. Our priorities were and still are clear: protecting the health and safety of our people while supporting business continuity for our customers and executing on the Advance 2025 strategy we set out in March. In Sustainable...

Corbion boekte een omzet van € 492,2 miljoen in het eerste halfjaar van 2020, een toename van 4,3% als gevolg van autonome omzetgroei (4,0%) en positieve valuta-effecten. De autonome groei van de netto-omzet bij de kernactiviteiten was 5,3%. De aangepaste EBITDA nam autonoom toe met 16,9% tot € 83,8 miljoen dankzij verbeteringen in alle bedrijfssegmenten.“De Covid-19-pandemie had een enorme impact in het eerste halfjaar van 2020. Ik ben daarom bijzonder trots op de toewijding en uitmuntende werkuitvoering van onze teams en de dankzij hen gerealiseerde omzet- en winstgroei in het eerste halfjaar, terwijl al onze fabrieken ondanks een onzekere en uitdagende tijd in bedrijf bleven. Onze prioriteiten waren en zijn nog steeds duidelijk: bescherming van de gezondheid en veiligheid van onze mensen, het ondersteunen van de bedrijfscontinuïteit...

SCANFIL OYJ              PUOLIVUOSIKATSAUS                         7.8.2020      KLO 8.00Vuoden 2020 ensimmäisen vuosipuoliskon aikana ei ollut oikaisueriä.SCANFIL OYJLiiteScanfil Oyjn puolivuosikatsaus 2020

SCANFIL PLC          HALF YEAR FINANCIAL REPORT                                                7 AUGUST 2020                     8.00 A.M.SCANFIL PLC: SCANFIL GROUP’S HALF YEAR FINANCIAL REPORT   1 JANUARY – 30 JUNE 2020 Q2/2020: Stable Development in Exceptional CircumstancesApril – June– Turnover totalled EUR 155.6 million (Q2 2019: 142.6), increase of 9.1%– Operating profit EUR 10.2 (6.4) million, 6.5% (4.5%) of turnover, adjusted operating profit in  the comparison year EUR 10.3 million, 7.2% of turnover– Net profit was EUR 8.3 (4.6) million– Earnings per share were EUR 0.13 (0.07)– On June 29, 2020, Scanfil announced the sale of the entire share capital of Scanfil (Hangzhou) Co., Ltd.,  a subsidiary located in Hangzhou, China.There were no adjustment items in 2020 during the first half of the year.SCANFIL...

• BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose• COVID-19 Phase 2 topline report to be submitted for consideration of emergency approval of leronlimab for patients with mild-to-moderate symptoms to U.K. and other countries following submission to the U.S. FDA next weekVANCOUVER, Washington, Aug. 06, 2020 (GLOBE NEWSWIRE) —  CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company, announced today it will submit requests for pre-submission meetings (equivalent to pre-BLA meeting in U.S.) in the U.K. for leronlimab as an HIV treatment in combination with HAART for highly treatment experienced HIV patients (350 mg dose, self-injectable, subcutaneous ), as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate...